Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Chunpu Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Shanghai Municipal Health and Family Planning Commission, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Small-molecule fibroblast growth factor receptor (FGFR) inhibitors have emerged as a promising antitumor therapy. Herein, by further optimizing the lead compound 1 under the guidance of molecular docking, we obtained a series of novel covalent FGFR inhibitors. After careful structure-activity relationship analysis, several compounds were identified to exhibit strong FGFR inhibitory activity and relatively better physicochemical and pharmacokinetic properties compared with those of 1. Among them, 2e potently and selectively inhibited the kinase activity of FGFR1-3 wildtype and high-incidence FGFR2-N549H/K-resistant mutant kinase. Furthermore, it suppressed cellular FGFR signaling, exhibiting considerable antiproliferative activity in FGFR-aberrant cancer cell lines. In addition, the oral administration of 2e in the FGFR1-amplified H1581, FGFR2-amplified NCI-H716, and SNU-16 tumor xenograft models demonstrated potent antitumor efficacy, inducing tumor stasis or even tumor regression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
ORCID-Profile: Mingyue Zheng, Hong Liu
Förderung
- China Postdoctoral Science Foundation
- Shanghai Municipal Health and Family Planning Commission
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Lingang Laboratory
Zitieren
APA
Li, C., Dai, Y., Kong, X., Wang, B., Peng, X., Wu, H., Shen, Y., Yang, Y., Ji, Y., Wang, D., Li, S., Li, X., Shi, Y., Geng, M., Zheng, M., Ai, J., & Liu, H. (2023). Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01507
Vancouver
Li C, Dai Y, Kong X, Wang B, Peng X, Wu H, et al. Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01507
BibTeX
@article{Li2023,
author = {Li, Chunpu and Dai, Yang and Kong, Xiangtai and Wang, Bao and Peng, Xia and Wu, Hengbo and Shen, Yanyan and Yang, Yanchen and Ji, Yinchun and Wang, Danyi and Li, Shuangjie and Li, Xutong and Shi, Yuqiang and Geng, Meiyu and Zheng, Mingyue and Ai, Jing and Liu, Hong},
title = {Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01507}
}
EUVIMED